​

Mereo BioPharma Group (MREO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

MREO Stock Forecast

Mereo BioPharma Group (MREO) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $0.83, with a high of $1.00 and a low of $0.50. This represents a 207.41% increase from the last price of $0.27.

- $1 $2 $3 $4 $5 High: $1 Avg: $0.83 Low: $0.5 Last Closed Price: $0.27

MREO Stock Rating

Mereo BioPharma Group stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (62.50%), 3 Hold (37.50%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 3 5 Strong Sell Sell Hold Buy Strong Buy

MREO Price Target Upside V Benchmarks

TypeNameUpside
StockMereo BioPharma Group207.41%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--5
Avg Price Target--$2.70
Last Closing Price$0.27$0.27$0.27
Upside/Downside--900.00%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 26143--8
Mar, 26241--7
Feb, 26241--7
Jan, 26242--8
Dec, 2526---8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 30, 2025Maury RaycroftJefferies$0.50$0.2972.41%85.19%
Dec 29, 2025Robert W. Baird$1.00$0.28257.14%270.37%
Dec 29, 2025BTIG$1.00$0.28257.14%270.37%
Dec 18, 2025Julian HarrisonBTIG$6.00$1.92212.50%2122.22%
Jul 10, 2025Gil BlumNeedham$5.00$1.87167.38%1751.85%
Jun 20, 2024Joseph SchwartzLeerink Partners$8.00$3.98101.01%2862.96%
Jun 12, 2024Jack AllenRobert W. Baird$8.00$3.83108.88%2862.96%
Jun 12, 2024Gil BlumNeedham$7.00$3.5298.86%2492.59%
Mar 28, 2024Gil BlumNeedham$6.00$3.00100.00%2122.22%
Aug 12, 2022Cantor Fitzgerald$4.00$1.35196.30%1381.48%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 30, 2025JefferiesHolddowngrade
Dec 29, 2025Cantor FitzgeraldOverweightOverweighthold
Dec 18, 2025BTIGBuyBuyhold
Jul 10, 2025NeedhamBuyBuyhold
Jun 12, 2024NeedhamBuyBuyhold
Mar 28, 2024NeedhamBuyBuyhold
Aug 12, 2022Cantor FitzgeraldOverweightinitialise
Jun 06, 2022NeedhamBuyBuyhold
Mar 17, 2022NeedhamBuyBuyhold
Apr 05, 2021NeedhamBuyinitialise

Financial Forecast

EPS Forecast

$-2K $-1K $-500 $0 $500 $1K Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$749.65$-1.10K$-0.29$-0.25---
Avg Forecast$-0.05$-0.04$-0.05$-0.02$-0.03$-0.01$0.05
High Forecast$-0.05$-0.03$0.10$0.01$-0.03$0.06$0.05
Low Forecast$-0.05$-0.04$-0.10$-0.04$-0.03$-0.05$0.05
Surprise %-1499400.00%2750450.00%480.00%1150.00%---

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$49.21M$10.00M-$500.00K---
Avg Forecast$18.43M$6.79M$14.48M$28.64M$33.64M$48.98M$111.19M
High Forecast$18.43M$6.79M$14.48M$28.64M$33.92M$48.98M$111.19M
Low Forecast$18.43M$6.79M$14.48M$28.64M$33.36M$48.98M$111.19M
Surprise %167.09%47.37%--98.25%---

Net Income Forecast

$-100M $-60M $-20M $20M $60M $100M Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$17.17M$-29.47M$-43.25M$-41.88M---
Avg Forecast$-30.86M$-21.17M$-33.86M$-17.33M$-17.27M$9.23M$34.55M
High Forecast$-30.86M$-19.24M$64.74M$3.42M$-17.27M$41.86M$34.55M
Low Forecast$-30.86M$-23.09M$-64.74M$-23.92M$-17.27M$-31.89M$34.55M
Surprise %-155.66%39.21%27.74%141.60%---

MREO Forecast FAQ

Is Mereo BioPharma Group stock a buy?

Mereo BioPharma Group stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Mereo BioPharma Group is a favorable investment for most analysts.

What is Mereo BioPharma Group's price target?

Mereo BioPharma Group's price target, set by 8 Wall Street analysts, averages $0.83 over the next 12 months. The price target range spans from $0.5 at the low end to $1 at the high end, suggesting a potential 207.41% change from the previous closing price of $0.27.

How does Mereo BioPharma Group stock forecast compare to its benchmarks?

Mereo BioPharma Group's stock forecast shows a 207.41% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Mereo BioPharma Group over the past three months?

  • April 2026: 12.50% Strong Buy, 50.00% Buy, 37.50% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 28.57% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 28.57% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.

What is Mereo BioPharma Group’s EPS forecast?

Mereo BioPharma Group's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.03, marking a -88.00% decrease from the reported $-0.25 in 2025. Estimates for the following years are $-0.01 in 2027, and $0.05 in 2028.

What is Mereo BioPharma Group’s revenue forecast?

Mereo BioPharma Group's average annual revenue forecast for its fiscal year ending in December 2026 is $33.64M, reflecting a 6628.75% increase from the reported $500K in 2025. The forecast for 2027 is $48.98M, and $111.19M for 2028.

What is Mereo BioPharma Group’s net income forecast?

Mereo BioPharma Group's net income forecast for the fiscal year ending in December 2026 stands at $-17.274M, representing a -58.75% decrease from the reported $-41.878M in 2025. Projections indicate $9.23M in 2027, and $34.55M in 2028.